Clinical Trial

An Intrinsic Capacity Identification and Management Programme for Older Adults in Singapore's Primary Care

Study acronym: IMPACTFrail
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 31, 2024 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
The IMPACTFrail program is an intrinsic capacity (IC) identification and management program for mildly frail older adults. Specifically, it delivers the three-tier approach recommended in the National Frailty Strategy Policy Report. The program's core functions include the segmentation of older persons using the Clinical Frailty Scale (CFS) score followed by secondary IC screening for CFS 4 to 5 (Tier 1), follow-up clinical assessment to confirm IC losses (Tier 2) and needs-directed management and tracking of their health (Tier 3). The investigator aims to conduct a multi-site feasibility study on a small group of older adult study participants (n=30 per polyclinic). The feasibility study has a few components. First, a qualitative study will assess its feasibility (implementation, appropriateness, acceptability, practicality, adaptability) as perceived by older adults, healthcare providers, and healthcare administrators. Second, the investigator aims to collect process indicators to track its implementation progress. Third, program costs will be estimated. Fourth, the investigator will develop a logic model and theory of change, and cluster-specific detailed written program descriptions. Lastly, the investigator aims to triangulate the findings and assess the feasibility for larger-scale implementation. This study is guided by implementation science frameworks and guidelines for conducting feasibility studies.
Trial Details
NCT Number NCT06753643
Lead Sponsor Geriatric Education and Research Institute
Collaborators: National Healthcare Group Polyclinics, National University Polyclinics, SingHealth Polyclinics
Conditions Healthy Ageing, Frailty
Enrollment 180 participants
Start Date 2025-03-01
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-12-31